Influences of cholinergic mechanisms on the function and turnover of brain dopamine.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D001479:Basal Ganglia / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002375:Catalepsy / Q000188:drug therapy; D003517:Cyclopentanes / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D006213:Hallucinogens / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology*; D006801:Humans; D008333:Mandelic Acids / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D010276:Parasympatholytics / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D012601:Scopolamine / Q000494:pharmacology; D014282:Trihexyphenidyl / Q000494:pharmacology
D003517:Cyclopentanes; D006213:Hallucinogens; D008333:Mandelic Acids; D010276:Parasympatholytics; D010880:Piperidines; D014282:Trihexyphenidyl; D001285:Atropine; D012601:Scopolamine; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine; D009638:Norepinephrine